Want to see AU:IXC full AI Analyst Report?
Top Page
Invex Therapeutics Ltd.
(Sydney:IXC)
Select Model
Select Model
Rating:52Neutral
Price Target:
AU$0.12
▲(0.83% Upside)
Action:Reiterated
Date:10/27/26
The score is held down primarily by weak financial performance (unstable/low revenue, ongoing losses, and persistent cash burn, despite having no debt). Technicals provide partial support with the stock trading above major moving averages and RSI indicating moderate strength, while valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Debt-free balance sheet
The absence of debt reduces mandatory interest and principal obligations, giving Invex greater flexibility while it develops its pipeline. A debt-free structure can also provide more resilience during periods of operating losses, although it does not eliminate the need to fund ongoing cash burn.
Negative Factors
Unstable revenue base
Highly inconsistent revenue and a reported return to zero revenue indicate that Invex does not yet have dependable commercial traction. Without sustained revenue generation, the company remains more exposed to development outcomes and external financing, making future planning and investment in its pipeline less financially secure.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of debt reduces mandatory interest and principal obligations, giving Invex greater flexibility while it develops its pipeline. A debt-free structure can also provide more resilience during periods of operating losses, although it does not eliminate the need to fund ongoing cash burn.
Read all positive factors
Invex Therapeutics Ltd. (IXC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$7.52M
Dividend Yield248.4%
Average Volume (3M)35.84K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue GrowthN/A
EPS Growth-185.71%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding75,153,850
10 Day Avg. Volume90,053
30 Day Avg. Volume35,838
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.73
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Invex Therapeutics Ltd. Business Overview & Revenue Model
Company Description
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurologic...
Invex Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 229.08K | 1.21M | 459.08K | 182.25K |
| Gross Profit | 0.00 | 229.08K | 1.21M | 459.08K | 182.25K |
| EBITDA | -1.54M | 0.00 | -720.37K | 337.94K | -4.14M |
| Net Income | -1.35M | -476.87K | -1.64M | -7.75M | -3.95M |
Balance Sheet | |||||
| Total Assets | 4.06M | 5.47M | 6.12M | 22.80M | 29.49M |
| Cash, Cash Equivalents and Short-Term Investments | 4.02M | 5.38M | 6.03M | 22.47M | 29.34M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 153.47K | 220.59K | 431.63K | 1.57M | 1.00M |
| Stockholders Equity | 3.91M | 5.25M | 5.69M | 21.23M | 28.48M |
Cash Flow | |||||
| Free Cash Flow | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Operating Cash Flow | -1.36M | -652.57K | -2.44M | -6.87M | -3.38M |
| Investing Cash Flow | -2.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | -14.00M | 0.00 | 0.00 |
Invex Therapeutics Ltd. Technical Analysis
Negative
0.12
Price Trends
0.11
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Negative
44.75
Neutral
47.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.75 is Neutral, neither overbought nor oversold. The STOCH value of 47.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.
Invex Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$7.52M | -5.56 | -31.98% | 248.40% | ― | -185.71% | |
52 Neutral | AU$12.36M | -1.67 | -247.44% | ― | -4.24% | 33.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$6.12M | -7.14 | -45.29% | 9.09% | 290.25% | 92.05% | |
43 Neutral | AU$5.74M | -1.07 | -52.04% | ― | 32.22% | -26.53% | |
42 Neutral | AU$33.15M | -0.37 | -118.74% | ― | 499.47% | 31.20% | |
42 Neutral | AU$13.49M | -9.91 | -29.22% | ― | ― | 81.00% |
* Healthcare Sector Average
AU:IXC
Invex Therapeutics Ltd.
0.10
-0.02
-13.04%
AU:ACR
Acrux
0.01
>-0.01
-28.57%
AU:TRP
Tissue Repair Ltd
0.10
-0.24
-71.21%
AU:CMB
Regeneus Ltd.
0.42
-0.11
-20.00%
AU:AGN
Argenica Therapeutics Ltd
0.11
-0.18
-62.50%
AU:BOT
Botanix Pharmaceuticals Limited
0.01
-0.12
-91.11%
Invex Therapeutics Ltd. Corporate Events
Invex Therapeutics Plans Major Equity Issue and New Performance Rights
Oct 25, 2026
Invex Therapeutics Ltd has notified the ASX of a proposed securities issue that includes 45 million new ordinary fully paid shares and a total of 91.25 million performance rights across three new classes, A, B and C. The proposed issue, structured...
Invex Therapeutics Plans Major ASX Securities Issue
Oct 25, 2026
Invex Therapeutics has announced a proposed issue of new securities on the ASX, comprising up to 113,750,000 fully paid ordinary shares and 19,500,000 options exercisable at $0.14 and expiring on 14 December 2029. The placement or other form of is...
Invex Therapeutics Halts ASX Trading Ahead of Acquisition and Capital Raising
Oct 21, 2026
Invex Therapeutics has requested a trading halt in its shares on the ASX, effective immediately, as it prepares to release a material announcement to the market. The halt will remain in place until either the company publishes details of a planned...
Invex Therapeutics Sets Date and Online Access for 2026 AGM
Oct 21, 2026
Invex Therapeutics has called its 2026 Annual General Meeting of shareholders for 20 November 2026 at 10:00am in Perth, Western Australia. The meeting notice, explanatory memorandum, annual report and proxy materials are available online via the c...
Invex Therapeutics Sets AGM Date and Director Nomination Deadline
Sep 25, 2026
Invex Therapeutics has scheduled its Annual General Meeting for 20 November 2026, with formal meeting documentation to be provided to shareholders in October. The company has set 2 October 2026 as the deadline for director nomination submissions, ...
Invex Therapeutics Posts Deeper Loss but Strengthens Asset Backing in 2026
Aug 31, 2026
Invex Therapeutics Ltd reported a significantly wider loss for the year ended 30 June 2026, with loss after tax attributable to members rising to $1.35 million as other income fell sharply compared with the previous year. Despite the deeper losses...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.